A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

Registry ID

C1071007

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA ULC

Start date

2023-06-16

Last update

2022-01-12

Conditions

• MYELOMA

Related clinical trials

• A RANDOMIZED, PHASE 3, OPEN LABEL STUDY EVALUATING SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
• A RANDOMIZED PHASE II, OPEN LABEL STUDY OF DARATUMUMAB, WEEKLY LOW-DOSE ORAL DEXAMETHASONE AND CYCLOPHOSPHAMIDE WITH OR WITHOUT POMALIDOMIDE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

View on source registry